Navigation Links
VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings
Date:10/20/2009

SARATOGA, Calif., Oct. 20 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for individuals with age-related macular degeneration (AMD), today announced upcoming scientific and corporate presentations on its implantable telescope technology. VisionCare's investigational telescope implant is the first medical device to be recommended for FDA approval by the FDA Ophthalmic Devices Advisory Panel for End-Stage AMD, a leading cause of untreatable blindness in the U.S.

    Three podium presentations are scheduled as follows:

    American Academy of Ophthalmology (AAO) Annual Meeting
    October 23 - 27, 2009 - Moscone Center, San Francisco.

        -  Friday, October 23
           Session: AAO Retina 2009 Subspecialty Day, Late Breaking
           Developments
           Location: Moscone Center South, Esplanade Ballroom

           3:28 PM Long-term Data on the Implantable Telescope Technology
           Jeffrey S. Heier, MD, Vitreoretinal Specialist, Ophthalmic
           Consultants of Boston, Boston, MA.

        -  Monday, October 26
           Session: AAO Joint Meeting, Symposium 25
           Location: Moscone Center South, Esplanade Ballroom

           5:14 PM Implantable Miniaturized Telescope
           Mark R. Wilkins, MD, Cornea/Cataract Specialist, Moorfields Eye
           Hospital, London.

    Ophthalmology Innovation Summit (OIS)
    October 22, 2009 - The Palace Hotel, San Francisco.

        -  8:50 AM VisionCare Ophthalmic Technologies
           Allen W. Hill, President and CEO

At the AAO annual meeting, VisionCare is in Booth #5437 located in the West Hall of the Moscone Convention Center.

About the Telescope Device

The investigational Implantable Miniature Telescope (by Dr. Isaac Lipshitz) is designed to be a solution for moderate to profound vision loss due to advanced, end-stage forms of AMD that have no current surgical or medical treatment options. Smaller than a pea, the telescope prosthetic device is implanted in one eye in an outpatient surgical procedure. In the implanted eye, the device renders enlarged central vision images over a wide area of the retina to improve central vision, while the non-operated eye provides peripheral vision for mobility and orientation. On March 27, the FDA Ophthalmic Devices Advisory Panel unanimously recommended that the FDA approve, with conditions, the premarket application (PMA) for VisionCare's device for End-Stage AMD. The telescope implant is the first medical device to be recommended by the panel for FDA approval for End-Stage AMD, a leading cause of untreatable blindness in the U.S. The company anticipates FDA approval within the next few months. The device has received CE Mark approval in Europe.

About Macular Degeneration

Macular degeneration is a disorder of the central retina, or macula, which is responsible for detailed vision that controls important functional visual activities like recognizing faces and watching television. According to the National Eye Institute over 1.7 million Americans over age 50 suffer mild to profound vision loss from advanced AMD, which frequently culminates as End-Stage AMD (visual impairment due to untreatable advanced AMD). Patients affected in both eyes often experience a loss of independence, social interaction, and have difficulty with activities of daily living requiring detailed vision. Approximately half of the individuals living with advanced AMD are affected in both eyes.

About VisionCare

VisionCare Ophthalmic Technologies, Inc., headquartered in Saratoga, CA is a privately-held company focused on development, manufacturing, and marketing of visual prosthetic devices. The Implantable Miniature Telescope was invented by company founders, Yossi Gross and Isaac Lipshitz. Information on VisionCare can be found at www.visioncareinc.net.

SOURCE VisionCare Ophthalmic Technologies, Inc.


'/>"/>
SOURCE VisionCare Ophthalmic Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
2. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
3. Implantable Defibrillators Lower Risk of Death in Older Heart Patients
4. Can Implantable Devices for Heart Failure Help Assess Risk of Future Adverse Events for Heart Failure Patients?
5. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
6. Accuray Ranked 155th Fastest Growing Company in North America on Deloittes 2009 Technology Fast 500(TM)
7. e-Zassi.com Provides Industry With Online U.S. FDA Regulatory Calculator for Rapid Medical Device Technology Assessment
8. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
9. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award
10. ECRI Institute Sees Upward Trend in Hospital Medical Technology Evaluation Activity
11. Verathon Introduces the GlideScope(R) Cobalt Advanced Video Laryngoscope (AVL); New Digital Technology Facilitates Quick Intubations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2017)... , June 30, 2017  AVACEN Medical (AVACEN) announced the publication ... research describes the use of its AVACEN Treatment Method ... from fibromyalgia. ... AVACEN Medical ... by chronic widespread pain. It affects approximately 200 to 400 million people ...
(Date:6/27/2017)...  Therapix Biosciences Ltd. (Nasdaq: TRPX ) ... development of cannabinoid-based drugs, today announced that the Company ... New York, NY on Wednesday, ... offering (IPO) of American Depository Shares (ADSs) listed on ... Dr. Elran Haber, Ph.D., Chief Executive Officer of Therapix, ...
(Date:6/20/2017)... and LAGUNA HILLS, Calif. , ... of new data that validate the use of MMprofiler ... patients with multiple myeloma (MM). In a poster presentation ... Hematology Association (EHA) in Madrid, Spain ... MMprofiler for identifying high-risk elderly patients. ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... Right now, behind ... The agency is hammering out a game plan to implement changes and compromises ... to affect FDA-regulated firms. The new law:, ,     Seeks ways ...
(Date:7/24/2017)... ... 2017 , ... “A Short Walk to the Mailbox”: a remarkable memoir of ... published author, Ed Clark. Ed Clark is a church music director and choral ... minister of music and worship leader for over fifty years. He has a ...
(Date:7/23/2017)... , ... July 23, 2017 , ... A 20-year-long ... St. Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly supports ... the disease offers very few benefits. , In the cases involved with this ...
(Date:7/23/2017)... ... July 23, 2017 , ... “I Am Not Nothin’: The Serpent ... who could barely read and write and a brokenhearted young soldier who turned to ... of age novel about the power of simple faith is the work of published ...
(Date:7/22/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 22, ... ... surgeries take place each year with the majority of patients not requiring pain ... American Orthopaedic Society for Sports Medicine’s Annual Meeting today in Toronto, Ontario, ...
Breaking Medicine News(10 mins):